BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 for Treating Acute Stress Disorder
BTAI Stock | USD 0.47 0.04 7.84% |
Under 66% of BioXcel Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding BioXcel Therapeutics suggests that many traders are alarmed. BioXcel Therapeutics' investing sentiment shows overall attitude of investors towards BioXcel Therapeutics.
BioXcel |
Phase 2a efficacy and safety trial enrollment initiation expected in H1 2025 40 million Americans go to emergency department annually after a traumatic experience 1 Second externally funded stress-related trial for BXCL501 NEW HAVEN, Conn., Oct. 15, 2024 -- BioXcel Therapeutics, Inc. , a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced a collaboration with the University of North Carol
Read at finance.yahoo.com
BioXcel Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards BioXcel Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BioXcel Therapeutics Fundamental Analysis
We analyze BioXcel Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioXcel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioXcel Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
BioXcel Therapeutics is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
BioXcel Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioXcel Therapeutics stock to make a market-neutral strategy. Peer analysis of BioXcel Therapeutics could also be used in its relative valuation, which is a method of valuing BioXcel Therapeutics by comparing valuation metrics with similar companies.
Peers
BioXcel Therapeutics Related Equities
AMLX | Amylyx Pharmaceuticals | 7.40 | ||||
APLS | Apellis Pharmaceuticals | 3.70 | ||||
HEPA | Hepion Pharmaceuticals | 3.03 | ||||
EXEL | Exelixis | 2.16 | ||||
ELEV | Elevation Oncology | 1.67 | ||||
TERN | Terns Pharmaceuticals | 1.40 | ||||
ABOS | Acumen Pharmaceuticals | 0.42 | ||||
MDGL | Madrigal Pharmaceuticals | 0.65 | ||||
VKTX | Viking Therapeutics | 1.14 | ||||
TGTX | TG Therapeutics | 1.31 | ||||
DAWN | Day One | 2.19 | ||||
INZY | Inozyme Pharma | 6.05 | ||||
XFOR | X4 Pharmaceuticals | 8.11 | ||||
MREO | Mereo BioPharma | 9.14 |
Complementary Tools for BioXcel Stock analysis
When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |